77 Adrenocortical carcinoma (ACC), a rare and aggressive form of cancer that originates in the adrenal cortex, has recently been the subject of a study by researchers at the University of Florence that offers encouraging new insights into its genetic profiling. The study uses a simplified targeted Next Generation Sequencing (NGS) panel to learn more about the mutational profiles of ACC and see how useful they are for predicting the outcome of the disease, especially in early stages. The findings were published in the European Journal of Endocrinology. ACC is a challenging cancer to manage due to its rarity and the variable prognosis depending on the tumour’s stage at diagnosis. The standard approach to treatment has long relied on clinical and histopathological evaluations, with surgical resection being the primary treatment option. However, even after surgery, local recurrences and metastases are common, underscoring the need for more precise prognostic tools and personalised treatment strategies. The study involved a retrospective analysis of 30 frozen tumour specimens from ACC patients treated at Careggi University Hospital in Florence. These samples were subjected to a custom-designed NGS panel, targeting 10 genes known to be frequently mutated in ACC. The results from this local cohort were then integrated with data from an additional 86 ACC patients from the ACC-TCGA series, creating a total cohort of 113 patients. One of the key findings from the study was the identification of specific gene mutations associated with worse clinical outcomes, particularly in patients with low-stage ACC. For example, having mutations in both the NF1 and TP53 genes together was found to greatly lower progression-free survival (PFS), with a 13.23 percent chance of dying in low-stage cases. In the same way, having mutations in both the Wnt/β-catenin and Rb/p53 pathways together was linked to an even higher risk of progression, with an HR of 16.24 in early stages. These findings suggest that certain genetic alterations can significantly influence the progression and overall survival of ACC patients, particularly in those diagnosed at an early stage. The study’s results indicate that incorporating genetic profiling into routine clinical practice could enhance the ability to stratify patients according to their risk of progression, allowing for more tailored and effective treatment approaches. The implications of this study are potentially far-reaching. By using a simplified targeted-NGS approach, which is both cost-effective and efficient, clinicians could routinely assess the genetic profiles of ACC tumours. This would enable more accurate prognostication and inform decisions regarding the intensity and nature of surveillance and treatment. One of the most promising aspects of the study is its potential to improve outcomes for patients with low-stage ACC. Traditionally, these patients have been considered at lower risk of progression, but the study’s findings suggest that specific genetic mutations can identify those who are at higher risk despite the early stage of their disease. This could lead to more aggressive treatment and closer monitoring for these patients, potentially improving their long-term outcomes. The study also highlights the importance of continuing research into the genetic underpinnings of ACC. While the current NGS panel focused on a select number of genes, the ongoing development of more comprehensive panels could further refine our understanding of the genetic drivers of ACC and their impact on patient outcomes. While the study’s findings are promising, the researchers acknowledge the need for further validation in larger, prospective studies. If more genes are added to future NGS panels along with other genetic changes like copy number changes and DNA methylation, it might be possible to get an even more complete picture of the genetic landscape of ACC.